Barr Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and marketing of pharmaceutical products. The company operates in two segments, Generic Pharmaceuticals and Proprietary Pharmaceuticals. The Generic Pharmaceuticals segment markets approximately 150 dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products, representing the category of its generic portfolio. It manufactures products in the form of tablets, capsules, and powder. The Proprietary Pharmaceuticals segment markets 13 proprietary pharmaceutical products, focusing in the female healthcare arena, including oral contraceptive and hormone therapy products; oncology; cardiovascular; anti-infective; and psychotherapeutic pharmaceuticals. These products include Aygestin, for amenorrhea; Cenestin line of hormone therapy products; Diamox and Sequels, for glaucoma; Loestrin/Loestrin Fe, and Nordette, for oral contraceptive; Plan B, for emergency oral contraceptive; Prefest, for hormone therapy; Revia, for alcohol dependence; SEASONALE, for extended-cycle oral contraceptive; Trexall, for rheumatoid arthritis; ViaSpan, for transplant preservation agent; and Zebeta and Ziac, for hypertension. Barr Pharmaceuticals markets its products to drug store chains, supermarket chains, mass merchandisers, wholesalers, distributors, managed care organizations, mail order accounts, government/military, and repackagers primarily in the United States and Puerto Rico. The company was founded by Edwin A. Cohen in 1970 and is headquartered in Woodcliff Lake, New Jersey.